FIELD: pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutics and molecular biology and concerns recombinant chimeric protein binding VPAC2 selective receptor, having amino acid sequence SEQ ID NO:13 and having N-terminal methionine and elastin-like polypeptide on c-end, which contains at least 60 repeats VPGXG, as well as pharmaceutical composition containing them.
EFFECT: group of inventions provides longer half-life of blood circulation system, efficiency of binding with receptors or biological activity and/or changed profile of binding with receptor.
10 cl, 8 ex, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| RECOMBINANT PROTEIN EXPRESSION IN DOUBLE-STRAND C FORM | 2006 |
|
RU2412253C2 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| ANTIBODY TO IL-13RA2 AND ITS APPLICATION | 2018 |
|
RU2756623C2 |
| HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| PHARMACEUTICAL COMPOSITION OF THE FUSION PROTEIN OF THE TRANSFORMING GROWTH FACTOR BETA RECEPTOR AND ITS APPLICATION | 2019 |
|
RU2791683C2 |
| HUMANISED HUMAN CD19 ANTIBODIES AND METHODS FOR USE THEREOF | 2016 |
|
RU2731156C1 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| NEW ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION | 2018 |
|
RU2805674C2 |
| CHIMERIC OSPA GENES, PROTEINS AND THEIR APPLICATION METHODS | 2011 |
|
RU2773402C2 |
